ChemoCentryx
About
What does ChemoCentryx do?
ChemoCentryx was a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small molecule therapeutics. Their primary focus was on inflammatory disorders and cancer, with a particular emphasis on targeting chemokine receptors and their ligands. The company's lead product, TAVNEOS (avacopan), was approved for the treatment of adult patients with severe active ANCA-associated vasculitis.
Where is ChemoCentryx headquartered?
ChemoCentryx is headquartered in San Carlos, United States.
What industry does ChemoCentryx operate in?
ChemoCentryx operates in Biotech, Drug Discovery, Clinical Trials, Inflammatory Disorders, Oncology, Pharmaceuticals.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
Spearmint Resources Inc. is a Canadian mineral exploration company focused on lithium, gold, and antimony projects.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
Feef is a voice-native AI agent that designs personalized fitness, nutrition, supplement, and recovery protocols, integrating them directly into your calendar.
Longevity and metabolic health platform offering personalized insights and interventions.
Discover innovative AI therapeutics at fibrotherapeutics.ai, enhancing patient care and advancing health technology.
An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.